Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Pediatric Genomic Medicine, |
RCV000442138 | SCV000511436 | pathogenic | not provided | 2016-12-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000087369 | SCV001585876 | pathogenic | Ehlers-Danlos syndrome, type 4 | 2023-12-26 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 46 of the COL3A1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with clinical features of Ehlers-Danlos syndrome (PMID: 22019127, 24922459; Invitae). ClinVar contains an entry for this variant (Variation ID: 101132). Studies have shown that disruption of this splice site results in skipping of exon 46, but is expected to preserve the integrity of the reading-frame (PMID: 22019127). This variant disrupts the triple helix domain of COL3A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL3A1, variants that affect these glycine residues are significantly enriched in individuals with disease (PMID: 24922459, 25758994) compared to the general population (ExAC). For these reasons, this variant has been classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000087369 | SCV003928694 | pathogenic | Ehlers-Danlos syndrome, type 4 | 2023-04-25 | criteria provided, single submitter | clinical testing | Variant summary: COL3A1 c.3417+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a canonical 5' splicing donor site. At least one publication reports experimental evidence that this variant indeed affects mRNA splicing and results in the in-frame skipping of exon 46 (e.g. PMID:22019127). This is expected to affect the triple-helical region of the encoded protein and alterations of glycine residues within the collagen triple-helix are common mechanisms of disease. The variant was absent in 251444 control chromosomes (gnomAD). c.3417+1G>A has been reported in the literature in individuals affected with Ehlers-Danlos Syndrome, Vascular Type (PMID: 22019127, 24922459). These data indicate that the variant is likely associated with disease. Two submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 and both classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Collagen Diagnostic Laboratory, |
RCV000087369 | SCV000120251 | pathogenic | Ehlers-Danlos syndrome, type 4 | no assertion criteria provided | clinical testing |